Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 8/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 6/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2644385 | 1.00 | CA1 (0.53) | CA1CA2FFAR1NR1H4EPHX2 | |
| SCHEMBL13778184 | 0.85 | CYP1A2 (0.54) | CA1CA2NR1H4EPHX2TRPV1 | |
| SCHEMBL13685217 | 0.85 | CYP1A2 (0.54) | CA1CA2NR1H4EPHX2TRPV1 | |
| SCHEMBL2643476 | 0.79 | CA1 (0.54) | CA1CA2FFAR1NR1H4EPHX2 | |
| SCHEMBL2643473 | 0.79 | CA1 (0.54) | CA1CA2FFAR1NR1H4EPHX2 | |
| SCHEMBL29129862 | 0.77 | NR1H4 (0.67) | CA1CA2FFAR1NR1H4EPHX2 | |
| SCHEMBL11462143 | 0.76 | EPHX2 (0.62) | CA1CA2NR1H4EPHX2TRPV1 | |
| SCHEMBL2653593 | 0.75 | NR1H4 (0.64) | CA1CA2NR1H4EPHX2HDAC8 | |
| SCHEMBL5184746 | 0.75 | CA1 (0.70) | CA1CA2NR1H4EPHX2TRPV1 | |
| SCHEMBL8461643 | 0.74 | CA1 (0.74) | CA1CA2NR1H4EPHX2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040116483-A1 | Glucagon antagonists/inverse agonists | BEHRENS CARSTEN (DK) | 2004-06-17 | — | — | US | disclosed |
| US-6649641-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-11-18 | — | — | US | disclosed |
| US-20030203946-A1 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-10-30 | — | — | US | disclosed |
| US-20020187982-A1 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2002-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020187982-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | CA1 4635/4885CA2 3400/4885FFAR1 32/4885 |
| US-20030203946-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | CA1 4635/4885CA2 3400/4885FFAR1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.